Novel Diagnostic and Therapeutic Approaches in Urologic Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 21 July 2026 | Viewed by 74
Special Issue Editor
Interests: urologic oncology; bladder cancer; prostate cancer; immunotherapy; precision medicine; geroscience
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Urologic oncology has experienced remarkable advancements in recent years, reshaping our understanding of cancers such as prostate, bladder, and kidney cancers. These malignancies represent a significant global health burden, driving a continuous search for improved diagnostic and therapeutic methods.
Historically, diagnostic approaches relied heavily on imaging and biopsy, while therapeutic strategies were mostly limited to surgery and radiotherapy. However, the evolution of molecular biology and targeted therapies has fundamentally transformed the field.
This topic aims to discuss the latest diagnostic innovations, such as liquid biopsies and imaging biomarkers, as well as emerging therapeutic modalities, including immunotherapy and targeted agents.
In this Special Issue, we highlight the recent integration of artificial intelligence in diagnostics, the development of novel biomarkers, and the promise of personalized therapy approaches that are pushing the boundaries of urologic oncology.
We welcome original research and comprehensive reviews that provide insights into these emerging diagnostic and therapeutic innovations in urologic oncology.
Dr. Whi-An Kwon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urologic oncology
- liquid biopsy
- immunotherapy
- artificial intelligence
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
